(Reuters) – Sanofi SA is near a deal to take over U.S. drug maker Bioverativ Inc for greater than $11.5 billion, the Wall Street Journal reported, citing folks accustomed to the matter.
The potential deal, which might be introduced as quickly as Monday, would worth Bioverativ at about $105 a share, the Journal reported. (on.wsj.com/2mYJulp)
The value represents a 64 % premium to Bioverativ inventory’s shut on Friday on the Nasdaq.
Bioverativ, a hemophilia drug maker, was separated from Biogen Inc early final yr.
Sanofi has didn’t land main offers after dropping California-based most cancers specialist Medivation to Pfizer Inc in 2016 and Swiss biotech firm Actelion to Johnson & Johnson final yr.
Earlier this month, Sanofi stated it obtained the fitting to develop and promote a brand new hemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals.
Sanofi and Bioverativ weren’t instantly obtainable for remark outdoors common enterprise hours.
Reporting by Shubham Kalia in Bengaluru; Editing by Paul Simao and Gopakumar Warrier